Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer

  • Jiang, Chang (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Liao, Fang-Xin (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Rong, Yu-Ming (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Yang, Qiong (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Yin, Chen-Xi (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • He, Wen-Zhuo (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Cai, Xiu-Yu (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Guo, Gui-Fang (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Qiu, Hui-Juan (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Chen, Xu-Xian (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Zhang, Bei (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center) ;
  • Xia, Liang-Ping (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
  • Published : 2014.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To compare the efficacy of taxane-based regimens in the first line setting retrospectively in Chinese patients with recurrent and/or metastatic esophageal cancer. Methods: We analyzed 102 recurrent and/or metastatic esophageal cancer patients who received taxanes-based regimens in a first-line setting from January 2009 to December 2013. Sixteen (15.7%) patients were administered Nab-PTX based chemotherapy and 86 patients (84.3%) received paclitaxel (PTX) or docetaxel (DTX) based chemotherapy. Patients in the PTX/DTX group could be further divided into TP (71 patients) and TPF (15 patients) groups. Results: The objective response rate (ORR) of all patients was 20.6%, and the disease control rate (DCR) was 67.6%. The median overall survival (OS) was 10.5 months (95% CI 10.1-16.4) and the median progression-free survival (PFS) was 6.04 months (95% CI 5.09-7.91). The DCR was higher in the TPF group than the TP group (93.3% vs. 59.1%; p = 0.015 ). There were no significant differences in ORR, OS, and PFS among Nab-PTX, TPF and TP groups. Conclusions: The three regimens of Nab-PTX based, TP and TPF proved active in a first line setting of Chinese patients with recurrent and/or metastatic esophageal cancer, and should thus be regarded as alternative treatments.

Keywords

References

  1. Ajani JA, Ilson DH, Daugherty K, et al. (1994). Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst, 86, 1086-91. https://doi.org/10.1093/jnci/86.14.1086
  2. Ajani JA, Fodor MB, Tjulandin SA, et al. (2005). Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol, 23, 5660-7. https://doi.org/10.1200/JCO.2005.17.376
  3. Al-Hajeili M, Azmi AS, Choi M (2014). Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther, 7, 187-92.
  4. Bang YJ, Van Cutsem E, Feyereislova A, et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. https://doi.org/10.1016/S0140-6736(10)61121-X
  5. Burtness B, Gibson M, Egleston B, et al. (2009). Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol, 20, 1242-8. https://doi.org/10.1093/annonc/mdn787
  6. Desai N, Trieu V, Yao Z, et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12, 1317-24. https://doi.org/10.1158/1078-0432.CCR-05-1634
  7. Desai NP, Trieu V, Hwang LY, et al. (2008). Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Grug, 19, 899-909. https://doi.org/10.1097/CAD.0b013e32830f9046
  8. Dubecz A, Solymosi N, Stadlhuber RJ, et al. (2014). Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century? a SEER Database analysis. J Gastrointest Surg, 18, 124-9. https://doi.org/10.1007/s11605-013-2345-8
  9. Einzig AI, Neuberg D, Remick SC, et al. (1996). Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol, 13, 87-93. https://doi.org/10.1007/BF02993858
  10. Esteban E, Gonzalez de Sande L, Fernandez Y, et al. (2003). Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol, 14, 1640-7. https://doi.org/10.1093/annonc/mdg456
  11. Fujita Y, Hiramatsu M, Kawai M, et al. (2008). Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Dis Esophagus. 21, 496-501. https://doi.org/10.1111/j.1442-2050.2007.00806.x
  12. Gu M, Li SY, Huang XE, et al. (2012). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91. https://doi.org/10.7314/APJCP.2012.13.11.5587
  13. Hsu Y, Sood AK, Sorosky JI (2004). Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity. Am J Clin Oncol, 27, 14-8. https://doi.org/10.1097/01.coc.0000045849.95834.6B
  14. Huang J, Cai RG, Meng PJ, et al. (2004). Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus. Chinese J Oncol, 26, 753-5.
  15. International Agency for Research on Cancer;GLOBOCAN 2012. Available from URL: http://www-dep.iarc.fr/CancerMondial.htm.
  16. Ilson DH, Ajani J, Bhalla K, et al. (1998). Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol, 16, 1826-34. https://doi.org/10.1200/JCO.1998.16.5.1826
  17. Ji FZ, Zhu WG, Yu CH, et al. (2013). A randomized controlled trial of intensity-modulated radiation therapy plus docetaxel and cisplatin versus simple intensity-modulated radiation therapy in II-III stage esophageal carcinoma. Chinese J Gastrointestinal Surgery, 16, 842-5.
  18. Jie. H, Kang. S (2011). The epidemiology, current status of management, challenge and future strategy for esophageal cancer in China. China Oncology, 21, 501-4.
  19. Jones SE, Erban J, Overmoyer B, et al. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol, 23, 5542-51. https://doi.org/10.1200/JCO.2005.02.027
  20. Lu YF, Liu ZC, Li ZH, et al. (2014). Esophageal/gastric cancer screening in high-risk populations in Henan Province, China. Asian Pac J Cancer Prev, 15, 1419-22. https://doi.org/10.7314/APJCP.2014.15.3.1419
  21. Mirinezhad SK, Jangjoo AG, Seyednejad F, et al. (2014). Impact of tumor length on survival for patients with resected esophageal cancer. Asian Pac J Cancer Prev, 15, 691-4. https://doi.org/10.7314/APJCP.2014.15.2.691
  22. Mizota A, Shitara K, Kondo C, et al. (2011). A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology, 81, 237-42. https://doi.org/10.1159/000334057
  23. Nakajima M, Kato H (2013). Treatment options for esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy, 14, 1345-54. https://doi.org/10.1517/14656566.2013.801454
  24. O'Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J (2013). Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat, 138, 829-37. https://doi.org/10.1007/s10549-013-2447-8
  25. Park SH, Lee WK, Chung M, et al. (2006). Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs, 17, 225-9. https://doi.org/10.1097/00001813-200602000-00015
  26. Petrasch S, Welt A, Reinacher A, et al. (1998). Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer, 78, 511-4. https://doi.org/10.1038/bjc.1998.524
  27. Roth AD, Fazio N, Stupp R, et al. (2007). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; epirubicin, cisplatin, fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol, 25, 3217-23. https://doi.org/10.1200/JCO.2006.08.0135
  28. Shah MA, Jhawer M, Ilson DH, et al. (2011). Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol, 29, 868-74. https://doi.org/10.1200/JCO.2010.32.0770
  29. Shi Y, Qin R, Wang ZK, Dai GH (2013). Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther, 6, 585-91.
  30. Sparreboom A, Scripture CD, Trieu V, et al. (2005). Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res, 11, 4136-43. https://doi.org/10.1158/1078-0432.CCR-04-2291
  31. Thallinger CMR, Raderer M, Hejna M (2011). Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy. J Clin Oncol, 29, 4709-14. https://doi.org/10.1200/JCO.2011.36.7599
  32. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  33. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. (2006). Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7. https://doi.org/10.1200/JCO.2006.06.8429
  34. Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002). Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99, 860-8. https://doi.org/10.1002/ijc.10427
  35. Von Hoff DD, Ervin T, Arena FP, et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl. J Med, 369, 1691-703.
  36. Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Natl Medical J China, 90, 1986-8.
  37. Wu S, Chen MY, Luo JC, Wei L, Chen Z (2012). Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma. Chinese J Oncol, 34, 873-6.
  38. Xing PY, Li JL, Wang Y, et al. (2013). Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer. Chin J Cancer Res, 25, 200-5.
  39. Zhang DS, Wang DS, Wang ZQ, et al. (2013). Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol, 71, 1065-72. https://doi.org/10.1007/s00280-013-2102-4
  40. Zhang P, Xie CY, Wu SX (2007). Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer. Chinese J Oncol, 29, 773-7.
  41. Zhang TR, Zhao T, Xu X, Gu XW, Pan YK (2010). Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy. Chinese J Oncol, 32, 791-4.
  42. Zhao J, He YT, Zheng RS, Zhang SW, Chen WQ (2012). Analysis of esophageal cancer time trends in China, 1989- 2008. Asian Pac J Cancer Prev, 13, 4613-7. https://doi.org/10.7314/APJCP.2012.13.9.4613

Cited by

  1. Clinical Observation and Therapeutic Evaluation of Rh-endostatin Combined with DP Regimen in Treating Patients with Advanced Esophageal Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6565
  2. Systematic Analysis of Pemetrexed-based Chemoradiotherapy for Patients with Locally Advanced or Metastatic Esophageal Cancer vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8475